Both the in vitro and in vivo studies showed that this nanoparticle delivery system could effectively deliver CTLA-4-siRNA into both CD4+ and CD8+ T cells, and could significantly increase the percentage of anti-tumor CD8+ T cells, therefore enhancing the antitumor immune responses (Li et al., 2016b). The gene discussed is CD8A; the disease is neoplasm.